XML 58 R27.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Disclosures (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Significant Expense | The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and nine months ended September 30:
| Three Months Ended September 30,
| 2025 |  | 2024
Operating expenses: |  |  |
Clinical product candidates | $ | 15,285 |  |  | 17,338 |
Pre-clinical product candidates | 480 |  |  | 359 |
Employee costs- research and development | 2,463 |  |  | 2,074 |
Employee costs-general and administrative | 1,661 |  |  | 1,575 |
Non-cash stock compensation | 3,614 |  |  | 1,910 |
Depreciation expense | 40 |  |  | 42 |
Professional fees and other segment expenses | 2,450 |  |  | 2,428 |
Total operating expenses | 25,993 |  |  | 25,726 |
Loss from operations | (25,993) |  |  | (25,726) |
Interest income | 419 |  |  | 776 |
Other income (expense) | (5) |  |  | 582 |
Net loss | $ | (25,579) |  |  | $ | (24,368) |
| Nine Months Ended September 30,
| 2025 |  | 2024
Operating expenses: |  |  |
Clinical product candidates | $ | 50,776 |  |  | 47,220 |
Pre-clinical product candidates | 825 |  |  | 760 |
Employee costs- research and development | 7,224 |  |  | 5,955 |
Employee costs-general and administrative | 5,305 |  |  | 4,279 |
Non-cash stock compensation | 7,555 |  |  | 6,541 |
Depreciation expense | 126 |  |  | 99 |
Professional fees and other segment expenses | 8,090 |  |  | 7,567 |
Total operating expenses | 79,901 |  |  | 72,421 |
Loss from operations | (79,901) |  |  | (72,421) |
Interest income | 843 |  |  | 2,961 |
Change in fair value of the tranche rights | — |  |  | (4,796) |
Other income (expense) | 1,186 |  |  | (1,076) |
Net loss | $ | (77,872) |  |  | $ | (75,332) |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration